TOI Association with Achieving a DR (per Endpoint Assessment Committee)a
| Improvement Magnitude, Points | Improvement Duration, Cycles | TOI Improvement Rate, Odds Ratiob (95% CI) |
|---|---|---|
| 5 | 1 | 2.8 (1.1–7.0) |
| 3 | 2.6 (1.0–6.9) | |
| 6 | 1 | 3.0 (1.2–7.8) |
| 3 | 2.9 (1.1–8.1) | |
| 4 | 3.1 (1.1–9.1) | |
| 7 | 1 | 3.1 (1.2–8.4) |
| 2 | 2.8 (1.1–7.6) | |
| 3 | 3.0 (1.0–9.4) | |
| 8 | 1 | 3.1 (1.1–8.5) |
| 2 | 2.8 (1.0–7.8) |
DR durable response, TOI Trial Outcome Index
aIntent-to-treat landmark analysis patients with ≥9 months’ follow-up evaluable for TOI improvement were included; only odds ratio of TOI improvement rates with corresponding P values <0.05 are shown. Full results are available in Additional file 1: Material
bOdds ratio (DR/non-DR) stratified by disease stage (IIIB/IIIC/IVM1a versus IVM1b/IVM1c) and line of therapy (first-line versus second-line or later therapy)